tirzepatide is fda approved approval for Zepbound (tirzepatide) injection, the first and only obesity treatment of its kind that activates both GIP and GLP-1 hormone receptors - Eli Lilly FDA-Approved Tirzepatide: A Game Changer

Do not double your dose to make up for a missed one

Past medical history was significant for morbid obesity (current weight 286 kg), pulmonary embolism and deep vein thrombosis 4 years prior, previously treated with warfarin

Got a specific injury (tendon, muscle, joint)

Scientists study it as a model for how activating two receptors together behaves differently from activating just one, comparing it against single-receptor GLP-1 compounds and newer triple-receptor designs like retatrutide

Do not rinse your mouth

DetailsHide details Medication$99/mo Membership$99/mo Total monthly cost, all-in$198/mo First month$138/mo Regular monthly cost$198/mo Compounded semaglutide Cash-pay only Promotional pricing ties to 3-month commitment with non-refundable shipped medication